Actinogen Medical Ltd (ACW.AX) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Australia · ISIN AU000000ACW3
Actinogen Medical Ltd financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 5.49 m AUD | – |
| Gross profit | 5.49 m AUD | -419,272.00 AUD |
| Operating income | -14.93 m AUD | -28.11 m AUD |
| EBIT | -15.35 m AUD | -28.11 m AUD |
| Net income | -14.73 m AUD | -15.38 m AUD |
| Diluted EPS – continuing operations | -0.00 AUD | -0.00 AUD |
Full history since 2006, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Actinogen Medical Ltd
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
More stocks
- KLX Energy Services Holdings, Inc. (KLXE)
- Nykode Therapeutics ASA (NYKD.OL)
- K2 Gold Corporation (KTO.V)
- DEEP FISSION, INC. (FISN)
- Solux Co. Ltd (290690.KQ)
- B’IN Live Co Ltd (6625.TW)
- Maple Gold Mines Ltd (MGM.V)
- Oriental Precision & Engineering Co.Ltd (014940.KQ)
- Multicampus Corporation (067280.KQ)
- Batulicin Nusantara Maritim Tbk PT (BESS.JK)
- Deokyang Energen Corporation (0001A0.KQ)
- HansBiomed Corporation (042520.KQ)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.